Study of the Immunological Pathophysiological Mechanisms Associated With Acute Respiratory Distress Syndrome
Condition(s) studied
Study summary
About 10% of patients admitted to the ICU suffer from ARDS, with a mortality rate of around 35-45%. The lack of therapeutic innovation in ARDS can be partly explained by the heterogeneity of patients included under this definition.
A better understanding of the pathophysiological mechanisms underlying the different patient phenotypes is essential to develop new therapeutic strategies.
Objectives:
To characterize the inflammatory profile of patients with ARDS using circulating biomarkers and single-cell RNA sequencing of pulmonary immune cells.
The investigators hypothesize that there is a correlation between the profile of serum biomarkers (inflammatory sub-phenotypes), the transcriptome of pulmonary immune cells.
Briefly the experimental scheme is as follow:
* Population: patients with ARDS under invasive mechanical ventilation in the ICU.
* Intervention:
1. Determination of the inflammatory subphenotype on circulatory inflammatory biomarkers.
2. Characterization of inflammation by single cell RNA sequencing on lung immune cells collected on broncho-alveolar fluid.
Eligibility
Primary outcome measure(s)
- Single cell RNA sequencing of pulmonary immune cells — At baseline
Single cell RNA sequencing of pulmonary immune cells collected during a bronchoalveolar lavage at inclusion.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hôpital Lariboisière | Paris | France | Recruiting |
More Assistance Publique - Hôpitaux de Paris trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07395076 on ClinicalTrials.gov ↗ ← All trials in France